

## Prevalidation of Salivary Biomarkers for Oral Cancer Detection

David Elashoff<sup>1</sup>, Hui Zhou<sup>4</sup>, Jean Reiss<sup>2</sup>, Jianghua Wang<sup>4</sup>, Hua Xiao<sup>4</sup>, Bradley Henson<sup>4</sup>, Shen Hu<sup>4</sup>, Martha Arellano<sup>4</sup>, Uttam Sinha<sup>6</sup>, Anh Le<sup>7</sup>, Diana Messadi<sup>4</sup>, Marilene Wang<sup>3</sup>, Vishad Nabili<sup>3</sup>, Mark Lingen<sup>8</sup>, Daryl Morris<sup>9</sup>, Timothy Randolph<sup>9</sup>, Ziding Feng<sup>9</sup>, David Akin<sup>4</sup>, Dragana A. Kastratovic<sup>10</sup>, David Chia<sup>2</sup>, Elliot Abemayor<sup>3</sup>, and David T.W. Wong<sup>4,5</sup>

### Abstract

**Background:** Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).

**Methods:** Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.

**Results:** Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.

**Conclusions:** The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.

**Impact:** Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects. *Cancer Epidemiol Biomarkers Prev*; 21(4); 664–72. ©2012 AACR.

### Introduction

Oral cancer [more than 90% are oral squamous cell carcinomas (OSCC)] is the sixth most common cancer worldwide with an average 5-year survival rate of approximately 60% (1). This poor survival rate has not improved in the past 3 decades despite improvements in therapeutic strategies. The key challenge to reduce

the mortality and morbidity of this disease is to develop strategies to identify and detect OSCC when it is at very early stage, which will enable effective intervention and therapy. Up to now, beyond conventional clinical oral examination, there are no scientifically credible, reliable early detection techniques available (1).

**Authors' Affiliations:** Departments of <sup>1</sup>Medicine and Biostatistics and <sup>2</sup>Pathology and Laboratory Medicine, <sup>3</sup>Division of Head and Neck Surgery/Otolaryngology, David Geffen School of Medicine, <sup>4</sup>School of Dentistry and Dental Research Institute, <sup>5</sup>Jonsson Comprehensive Cancer Center, University of California at Los Angeles; <sup>6</sup>Otolaryngology/Head and Neck, University of Southern California, Keck's School of Medicine; <sup>7</sup>Division of Endodontics, Oral and Maxillofacial Surgery and Orthodontics, Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry of University of Southern California, Los Angeles, California; <sup>8</sup>Department of Pathology, University of Chicago, Chicago, Illinois; <sup>9</sup>Bio-statistics Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; and <sup>10</sup>Clinical Center of Serbia, Pasterova, Belgrade, Serbia

**Note:** Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

D. Elashoff, H. Zhou, J. Reiss, and J. Wang are joint first authors.

D. Chia, E. Abemayor, and D.T.W. Wong are joint senior authors.

Hui Zhou's current affiliation: Genome Sciences Resource, Vanderbilt University Medical Center, Nashville, TN, Email: [usczhou@gmail.com](mailto:usczhou@gmail.com).

**Corresponding Author:** D.T.W. Wong, School of Dentistry, University of California at Los Angeles, 10833 Le Conte Avenue, 73-017 CHS, Los Angeles, CA 90095. Phone: 310-206-3048; Fax: 310-825-7609; E-mail: [dtwww@ucla.edu](mailto:dtwww@ucla.edu)

doi: 10.1158/1055-9965.EPI-11-1093

©2012 American Association for Cancer Research.

Saliva is a valuable body fluid for disease diagnosis, due to its noninvasive nature, and has been increasingly used as a source for discovery of oral cancer biomarkers (2–6). The ability to detect molecules in saliva from patients with head and neck cancer (7–9) provides unique opportunities to develop noninvasive diagnostics. Salivary molecules have already been proposed as potential oral cancer biomarkers. For example, salivary soluble CD44 (3, 10), salivary Cyfra 21-1, tissue polypeptide anti-gene, and CA125 have been proposed as oral cancer markers (6). Nevertheless, no single biomolecule has been shown to meet the real-world requirement for high accuracy in identifying early disease onset, suggesting that multiple biomarker candidates are needed for high accuracy and sensitivity in detecting OSCCs. In addition, extensive and rigorous biomarker validation will be crucial to the acceptance of newly discovered biomarker candidates before adoption for clinical use.

Global profiling of disease-associated molecules, such as proteins, DNA, mRNA, microRNA, and metabolites is becoming the state-of-the-art method to provide promising disease biomarker candidates. The ability to globally profile these molecules in saliva, through transcriptomic (7) and proteomic (5, 11) approaches, as well as the ability to detect specific molecules in saliva will greatly enhance the opportunities to identify reliable oral cancer biomarkers. Our prior salivary transcriptomic studies have discovered 7 OSCC-associated salivary RNAs (IL-8, SAT, IL-1B, OAZ1, H3F3A, DUSP, S100P). Initially, the levels of these RNAs were measured in a training set of 32 OSCC/32 control by quantitative PCR, and a logistic regression model including 4 markers (IL-8, SAT, IL-1B, and OAZ1) achieved a cross-validation prediction accuracy rate of 81% showing their potential as biomarkers for oral cancer detection (7). This has opened a new avenue for salivary biomarker discovery for human diseases. Here, we first report our follow-up validations of these oral cancer biomarkers in 2 independent cohorts in our laboratory. We also described our efforts in standardizing of methods used in the validation process of these salivary biomarkers. In addition, we have detailed the outcomes of another 3 independent validations conducted in collaboration with the National Cancer Institute's Early Detection Research Network (NCI-EDRN)'s Biomarker Reference Laboratory (BRL). The entire salivary biomarker assays for mRNAs and proteins have been streamlined and automated to minimize interlaboratory variance.

## Materials and Methods

### Subjects

Patients and control subjects were recruited at the Medical Centers at the University of California at Los Angeles (UCLA; Los Angeles, CA) and University of Southern California (USC; Los Angeles, CA) and Veteran

Hospital in greater Los Angeles (VAGLA; Los Angeles, CA) from year 2004 to 2007. We enrolled patients diagnosed with primary OSCC stage I–IV (T1–T4) according to the TNM (tumor-node-metastasis) criteria without previous chemotherapy or radiotherapy. All the protocols used in this study were approved by the Ethics Review Boards, Institutional Review Board at UCLA, and at all of the participating institutions. All participants provided written informed consent before saliva collection.

We sequentially recruited 5 retrospective case-control groups in which the disease status was known at time of subject recruitment. These 5 groups are described as cohort 1 through cohort 5 throughout. Cohorts 1 and 2 were configured with matched sex distributions among the subjects. Cohorts 3–5 were distributionally matched for age, sex, ethnicity, and smoking history. Controls were selected on the basis of matched criteria from enrolled populations from "spit drives" at the UCLA Medical Center without a prior history and diagnosis of head and neck cancer.

### Saliva collection

Unstimulated whole saliva was collected according to our published protocol (7), with modifications and supernatant saliva processed the same way as reported (12) and stored as SUPERASE-In or protease inhibitor-preserved salivary supernatant.

### Primer design

Primers (set 1) designed for real-time PCR has been described in the work of Li and colleagues (7, 12) and was used in study cohorts 1 and 2. Primers (set 2) were used in generating templates for *in vitro* transcription of RNA to produce standard RNA curves. The sequence were based on set 1 but extended to both 5' and 3' ends with T7 promoter sequences fused to the 5' end of each sense primer. The primers were designed by using Primer3. All primers were BLAST-searched against GenBank to confirm the gene specificity. Primers were synthesized by Sigma-Aldrich.

### Generation of *in vitro* transcribed RNA for standard curves of the 7 salivary RNA oral cancer markers

To generate templates for *in vitro* transcription for the 7 salivary oral cancer RNA markers, conventional real-time PCR (RT-PCR) was carried out using total RNA from human OSCC cell line as templates. The cDNA was synthesized in 20  $\mu$ L of reverse transcription reaction mix with 50 U MuLV reverse transcriptase (Applied Biosystems), 20 U RNase inhibitor (Applied Biosystems), 10 mmol/L dNTPs, and 5 nmol/L random hexamers. One-microliter aliquots of cDNA were used in a 20- $\mu$ L PCR reaction with 400 nmol/L set 2 primers at the PCR condition of 95°C for 3 minutes followed by 40 cycle of 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds, and final extension at 72°C for 7 minutes. RT-PCR products were confirmed on a 2% agarose gel stained with ethidium bromide. *In vitro* transcription was conducted

using T7 MEGAscript transcribe kit (Ambion). The resultant RNA transcripts were purified with column-based RNA clean up module (Arcturus). The cRNAs were quantified with Nanodrop spectrometry ND-1000 for quantity and quality ( $A_{260}/A_{280}$  ratio). Aliquots from the same standard stock for each of the salivary RNA biomarkers were used in all qPCR reactions.

#### Total salivary RNA extraction, cDNA synthesis

Total RNA was extracted according to the following procedures for the first 2 cohorts: frozen RNA later preserved as saliva (containing equal volume of raw saliva) was thawed on ice and total RNA was extracted using Viral Mini Kit (Qiagen) according to manufacturer's instructions. The resultant total RNA was eluted in 40  $\mu$ L of elution buffer and was treated with rDNase I (Ambion) according to manufacturer's instruction for 30 minutes at 37°C to remove any genomic DNA contamination. After inactivating DNase, purified total RNA aliquots were stored at -80°C until use.

Starting from cohort 3 and all the EDRN studies, SUPERASE-preserved supernatant saliva was used with a semi-automated robot (KingFisher, Thermo Scientific) and MagMix viral RNA mini kit (Ambion) in total RNA isolation. Briefly, 300  $\mu$ L samples were mixed with magnet beads and binding enhancer (1:1, total 20  $\mu$ L) and then with lysis buffer for 10 minutes at room temperature before adding 800  $\mu$ L isopropanol. The total lysates were then transferred into the plastic holder and the automated RNA isolation was started. The resulting purified RNAs were eluted into 100 elution buffer with DNase I (Ambion) treatment as described above.

For cDNA synthesis, 1  $\mu$ L of RNA standards (containing  $10^2$  to  $10^8$  copy number of IVT RNA), 1  $\mu$ L of salivary RNA was reverse transcribed with 50 U of MuLV reverse transcriptase (Applied Biosystems), using gene-specific primers (downstream primer of set 1) in a total volume of 20  $\mu$ L at the following condition: incubation at 25°C for 10 minutes, reverse transcribed at 42°C for 45 minutes followed by inactivation at 95°C for 5 minutes. The resulting cDNAs were stored at -20°C until later use.

#### SYBR-based quantitative real-time PCR

Quantitative PCR was carried out in triplicate for each sample in a 3-step protocol using melting curve method. PCR amplification of the 7 salivary marker mRNAs was carried out in a 20  $\mu$ L reaction mix containing a final concentration of 400 nmol/L sense and antisense primers, 3  $\mu$ L cDNA (salivary cDNA) or 2  $\mu$ L standard cDNA, and mixed with 10  $\mu$ L 2 $\times$  SYBR Green I Master mix (Applied Biosystems). All PCR reactions were carried out on ABI 7500 Fast Thermal Cycler.

#### Methods for NCI-EDRN-BRL validation

*Development of standardized protocols and automation to enhance biomarker validation.* The NCI-EDRN is a dedicated entity committed to make molecular diagnostics for cancer a clinical reality. We subjected our salivary oral cancer biomarkers to a phase II validation study with an EDRN-BRL to assess the reproducibility of the oral cancer salivary biomarkers. Initially, technical and methodologic information was transferred, via hands-on training, to the operator in an NCI-EDRN-sponsored laboratory. Experimental protocols were optimized in the following ways. First, by incorporating semiautomation into the RNA isolation step, operator variance was reduced and reproducibility in RNA recovery efficiency was improved. Second, high-throughput multiplex RT and a novel one-step RT-PCR preamplification method developed in our laboratory (13) to analyze multiple targets in a single reaction were used. Third, the automated liquid handling robot in the PCR setup procedures was applied. With these technical improvements in place, the NCI-EDRN laboratory conducted independent assays for the salivary oral cancer biomarkers on 3 different independent cohorts. Table 1 provides an overview of different experimental methods we used to assay the cohorts in each laboratory (cohorts 3–5 were assayed at EDRN-BRL).

#### RT-PCR preamplification

We have optimized a preamplification procedure for salivary mRNA for oral cancer target detection, and

**Table 1.** Comparison of materials and methods used in the 5 OSCC salivary mRNA biomarker validation studies

Data set	Sample size (OSCC/control)	Type of saliva	RNA isolation	Concentration determination	Priming	RT and PCR strategy	Equipment including BioMek 300 liquid handling
Cohorts 1, 2	48/48; 24/24	Whole saliva (1,120 $\mu$ L)	QIAamp Viral RNA Mini-Kit (Qiagen)	Cq	Mixed oligo random	Multiplex RT, two-step RT-PCR	BioRad iQ5 Manual baseline
Cohorts 3, 4, 5	30/30; 54/36; 70/31	Supernatant (300 $\mu$ L)	Ambion Viral RNA Kit	Cq	Nested gene-specific primers	Preamplification RT and PCR	ABI 7500 fast

detailed methods for primer design, one-step RT and PCR, excess primer removal, and quantitative PCR programming have been described previously (13). Primers for preamplification and quantitative PCR were designed as intron-span and sequence can be found in Supplementary Table S2. The reactions were set up using the BioMek 3000 Liquid Handling Platform into 96-well plates on PCR plate cooler.

### Salivary protein detection

Salivary interleukin (IL)-8, IL-1B and M2BP proteins were detected with specific ELISA kits (Pierce) according to manufacturer's instruction. M2BP is a tumor antigen (14–16) found to be significantly upregulated in nasopharyngeal carcinoma. The serum levels of M2BP were also significantly elevated in both patients with nasopharyngeal carcinoma and nasopharyngeal carcinoma nude mice model compared with healthy people or tumor-free mice (17).

Optimal dilutions for saliva are 1:8 for IL-8, 1:3 for IL-1B, and 1:20 for M2BP. All samples were assayed in same plate in duplicates. Results were obtained by microplate reader and converted into picogram per milliliter according to the standard curve with the standards provided.

### Statistical methods

All the statistical analyses were conducted using the statistical software R 2.9.1 and Bioconductor 2.5 (packages: ROC, meta). Means and SDs were calculated for both OSCCs and control samples for each marker in each cohort. Differential expression of each marker was assessed within each cohort by using the Mann–Whitney *U* test to determine statistical significance and by constructing a receiver operating characteristic (ROC) curves. The area under the curve (AUC) of the each of the ROC curves was obtained by numerical integration. Sensitivity and specificity were assessed for each marker in each cohort by using an expression cutoff point corresponding to the value of the *p*th percentile for the marker, where *p* is the proportion of OSCC cases in the cohort under consideration.

For meta-analysis of the individual markers, the estimates of sensitivity and specificity were used to generate a combined estimate using both fixed- and random-effects inverse variance meta-analysis models (18). These models were constructed separately for the sensitivity and specificity and were weighted proportionally to the relevant sample sizes in each study. The individual cohort sensitivities and specificities were used instead of the original marker values because of the differences in the measurement scales across the experiments and the differences in the proportions of OSCC cases in each cohort. We also conducted a meta-analysis to compare marker expression between cancer and controls. This analysis used a *z*-transformation within each group to normalize the expression levels across cohorts and then used a mixed-effect model to compare the *z*-transformed values between cancer and controls.

For the classification model evaluation, logistic regression was used to examine the use of combinations of markers for OSCC classification. For each cohort, we constructed 2 models. First, we used the same 4 markers (IL-8 + IL-1B + SAT + OAZ1) as in our original report (7) in each cohort. Next, we used forward stepwise regression within each cohort to identify the best 4 markers for each individual cohort. The AUC was computed by constructing an ROC curve using the predicted probabilities from each logistic model and then numerically integrating the curve. Sensitivity and specificity for the models were computed using the same method as for the individual marker models.

## Results

### Technical variations between the validation studies

Table 1 summarizes the technical details, modifications, and improvements that were made to improve the robustness and reproducibility of the salivary assays. A number of experimental parameters were evaluated. For RNA isolation, the Qiagen Viral RNA Mini-kit was first used for the first 2 cohorts. Upon working with the NCI-EDRN group, it became clear that to minimize assay variance, automated RNA isolation and liquid handling were necessary. We found the KingFisher automated RNA extractor and the BioMek 300 liquid handler to be of greatest value. Upon working with the EDRN-BRL, we also switched from the BioRad iQ5 to the ABI 7500 fast equipment for qPCR. Primer designs and qPCR strategies started with mixed oligonucleotide random primers. Gene-specific priming improved the specificity and this was further modified by our finding that preamplification of RNA targets using gene-specific primers followed by PCR significantly increased the robustness and the ability to assay small amount of salivary RNA.

### Population cohorts

Table 2 reports the demographic characteristics of the subject cohorts. The average age for healthy controls was significantly lower than OSCC subjects for cohorts 1 and 2. For example in cohort 1, controls had an average age of 31 years whereas patients with OSCC averaged age of 63 years. Age was not significantly different in the later 3 cohorts due to distributional age matching. We have staging for 55 of the subjects from the later 3 cohorts. For these subjects, 13 (24%) were stage I, 9 (16%) were stage II, 21 (38%) were stage III, and 12 (22%) were stage IV.

### Validation of the biomarkers in five independent cohorts

Since the publication of our initial discovery of 7 candidate mRNA biomarkers for OSCC detection almost 7 years ago (7), the behavior of the 7 oral cancer mRNA candidate biomarkers has been evaluated in 5 population-based, case–control studies totaling 395 subjects. All 7

**Table 2.** Demographic information (gender, ethnicity, and age) for individual biomarkers across the 5 independent cohorts

	Cohort 1		Cohort 2		Cohort 3		Cohort 4		Cohort 5	
	Control (N = 48)	OSCC (N = 48)	Control (N = 24)	OSCC (N = 24)	Control (N = 30)	OSCC (N = 30)	Control (N = 54)	OSCC (N = 36)	Control (N = 70)	OSCC (N = 31)
Gender										
Male	33	32	14	14	20	21	50	30	61	26
Female	15	16	10	10	10	9	4	6	8	4
Ethnicity										
Caucasian	29	32	15	19	16	23	42	26	55	23
Asian	12	2	4	3	4	1	0	2	8	3
Hispanic	2	4	3	2	3	1	3	3	6	4
African-American	5	2	2	0	7	2	9	6	0	0
Age, y										
Mean (SD)	31.4 (12.7)	62.7 (12.1)	41.1 (13.4)	64.9 (15.2)	51.5 (11.4)	54.5 (8.)	59.9 (9.1)	58.8 (13.5)	60.7 (10.0)	63.3 (11.0)

markers were increased in OSCC saliva versus controls in all 5 cohorts (Table 3). The number of salivary RNA markers showing a significant increase ( $P < 0.05$ ) varied across the cohorts from a minimum of 2 in cohorts 1 to a maximum of 7 in cohort 2.

Cohorts 1 (48 controls/48 OSCC) and 2 (24/24) were validation studies done at UCLA. The technical procedures were similar between the 2 experimental sets with the exception that gene-specific primers were used for the qPCR assays.

Cohorts 3 (30/30), 4 (54/36), and 5 (70/31) were assayed at the NCI-EDRN-BRL using samples procured at UCLA clinical affiliates. Before the independent assay being carried out at EDRN-BRL, a series of assay transfer and standardization steps were taken and installed as standard operating procedure. These included saliva collection, processing, stabilization, and storage (Supplementary Information S1). Using these as standard operating procedures and assaying the same clinical salivary samples at both the UCLA and NCI-EDRN-BRL, we found that the correlation of expression results for the OSCC salivary mRNA biomarkers were very high, ranging from 0.8 (DUSP1) to 0.96 (IL-8 and IL-1B; Fig. 1).

For the EDRN-BRL assayed cohorts, we found that 3 markers significantly increased in OSCC for cohort 3 (IL-8, SAT, and S100P); 4 markers were significantly increased for cohort 4 (IL-8, IL-1B, SAT, and OAZ1), and 6 markers for cohort 5 (IL-8, IL-1B, SAT, OAZ1, HA3, and DUSP1) of which 7 were significantly elevated ( $P < 0.05$ ). Note that for cohorts 4 and 5 we have included the evaluation of 3 salivary protein markers for oral cancer (IL-8, M2BP, and IL-1B; refs. 5, 7). For cohort 4, both IL-8 and M2BP proteins showed a significant increase in the patients with OSCC ( $P < 0.05$ ; not enough samples for IL-1B) whereas for cohort 5, IL-8 and IL-1B showed a significant increase ( $P < 0.05$ ).

Overall, with respect to individual marker performance, IL-8 and SAT were significantly increased in all cohorts whereas the other markers were significant in

only 3 cohorts (IL-1B, DUSP1, OAZ1, and HA3) and 2 cohorts for S100P.

#### Meta-analysis of performance of the markers across cohorts

Performance of individual markers was evaluated across the 5 independent cohorts, and individual estimates of sensitivity and specificity were extracted from each study. IL-8, IL-1B, and SAT are the top performers across different cohorts in terms of sensitivity and specificity, from 0.61 to 0.79. Combined estimates were calculated using fixed- and random-effects models. The 2 types of models gave similar results and we report the results of the random-effects model in Table 4. Overall, there was not a significant amount of heterogeneity across the cohorts (Cochran's  $Q$  value was generally smaller than the degrees of freedom and the estimate of  $\tau$ -squared was zero). Combined sensitivities from the random-effects model were 0.68, 0.65, and 0.66 and specificities were 0.64, 0.60, and 0.63 for IL-8, IL-1B and SAT, respectively (Table 4).

In addition, we conducted a meta-analysis to assess an overall significance level of the markers across the cohorts. We found that all 7 RNA markers were significantly differentially expressed between cancer and controls across the cohorts (all  $P < 0.02$ ). In addition, we found that IL-8 and M2BP proteins were also significantly different ( $P < 0.02$ ) and that IL-1B protein was marginally so ( $P = 0.053$ ).

#### Combination models for OSCC classification across the cohorts

The performance of the original previously described (7) 4-marker model (IL-8 + IL-1B + SAT + OAZ1) was evaluated across the independent cohorts. The AUCs derived from the fitted probability estimates from the logistic regression model ranged from 0.74 to 0.86 across the cohorts. The level of model performance was comparable with the best panel of markers (using stepwise

Table 3. Statistics [mean (SD) and AUC] for individual markers across 5 independent cohorts

	Cohort 1			Cohort 2			Cohort 3			Cohort 4			Cohort 5		
	Control (N = 48)	OSCC (N = 48)	AUC	Control (N = 24)	OSCC (N = 24)	AUC	Control (N = 30)	OSCC (N = 30)	AUC	Control (N = 54)	OSCC (N = 36)	AUC	Control (N = 70)	OSCC (N = 31)	AUC
mRNA (qPCR)															
DUSP1	35 (2.9)	34.3 (4.3)	0.58	33.1 (2.5)	30.8 <sup>a</sup> (3.3)	0.76	23.1 (5.2)	21.5 (4.1)	0.59	21.4 (2.5)	20.5 (2.3)	0.61	19.9 (3.5)	18.3 <sup>a</sup> (2.2)	0.64
H3F3A	34.5 (2.3)	34.4 (3.6)	0.52	34.1 (2.3)	32.0 <sup>a</sup> (3.5)	0.74	22.4 (3.6)	21.1 (2.9)	0.63	23.1 (2.1)	22.3 (2.2)	0.62	21.2 (3.4)	19.4 <sup>a</sup> (2.5)	0.65
IL-1B	30.9 (2.4)	29.8 (4.1)	0.63	29.1 (2.1)	27.0 <sup>a</sup> (2.9)	0.76	19.8 (3.4)	18.3 (3.0)	0.66	20.1 (2.9)	18.8 <sup>a</sup> (2.5)	0.64	18.7 (3.4)	17.0 <sup>a</sup> (2.1)	0.68
IL-8	33.8 (2.2)	32.4 <sup>a</sup> (3.6)	0.66	30.9 (2.5)	27.7 <sup>a</sup> (3.9)	0.83	19.6 (3.3)	17.4 <sup>a</sup> (2.8)	0.75	19.8 (2.9)	17.7 <sup>a</sup> (2.6)	0.72	18.6 (4.0)	16.8 <sup>a</sup> (2.2)	0.66
OAZ1	35.4 (2.4)	34.7 (3.8)	0.57	32.0 (2.5)	30.1 <sup>a</sup> (2.6)	0.73	23.6 (3.5)	22.2 (2.8)	0.65	24.3 (1.9)	23.5 <sup>a</sup> (2.2)	0.64	22.2 (2.4)	20.6 <sup>a</sup> (2.4)	0.69
S100P	32.4 (2.3)	31.9 (3.8)	0.58	30.7 (2.4)	28.4 <sup>a</sup> (2.5)	0.78	24.6 (4.7)	22.5 <sup>a</sup> (3.3)	0.66	23.1 (2)	22.5 (2.5)	0.59	22.6 (2.66)	21.7 (2.5)	0.61
SAT	31.7 (2.2)	30.3 <sup>a</sup> (3.8)	0.66	29.1 (2.5)	26.4 <sup>a</sup> (2.9)	0.80	20.7 (4.1)	18.7 <sup>a</sup> (3.0)	0.69	21.3 (2.3)	19.9 <sup>a</sup> (2.5)	0.68	19.8 (3.3)	18.4 <sup>a</sup> (3.1)	0.67
Protein (ELISA)															
IL-8										808 (1,132)	2,563 <sup>a</sup> (2,179)	0.76	739 (1,002)	2,140 <sup>a</sup> (2,282)	0.68
M2BP										549 (998)	998 <sup>a</sup> (741)	0.73	968 (765)	1,012 (873)	0.49
IL-1B													169 (202)	293 <sup>a</sup> (396)	0.57

<sup>a</sup>P < 0.05.

model selection separately in each cohort, "selected" models) where the AUC ranged from 0.75 to 0.86. The original 4 salivary RNA marker model was the selected model in cohort 2. Overall the selected models only improved AUCs by an average of 0.03 (Table 5). In addition, we found that IL-8 was selected for all 5 models and SAT was selected for 4 of the models, suggesting that these 2 markers have the most consistent predictive ability.

## Discussion

To substantiate the development of salivary biomarkers, we assessed the original putative OSCC markers in 395 subjects, in 5 independent validation cohorts. In this article, we describe 2 important validation steps: first, we independently validated the behavior of these biomarker candidates in multiple cohorts and second, we showed the reproducibility and robustness of the assays in an outside reference laboratory.

Patients within each cohort consisted of stage I to IV oral cancers, which represent the entire spectrum of OSCCs (19). The expression levels of these markers were not significantly associated with tumor stage in the cohorts tested (data not shown); therefore, it appears that this panel of 7 OSCC biomarkers may not be indicative of disease progression. This finding might be explained by the hypothesis that the mRNA signatures do not come from a tumor cell origin but rather a tumor-induced response (20). Further studies testing this hypothesis would indeed be intriguing. Nevertheless, these data support the important assertion that these biomarkers are associated with oral cancer. For the validated salivary biomarkers, the shown high sensitivity, specificity, discriminatory value, and low-cost support their potential use for disease screening purposes in at-risk populations.

We conducted multiple validation studies in which slightly modified technological adjustments were made to decrease interoperator and intersample variations. For example, to minimize the sample loading variations between individual PCR setups, we used robot liquid handling, which greatly improved the sample loading accuracy. The operator conducting the experimental procedures, protocol, and even equipment can play an important role in data compatibility. To show the robustness of the assay and minimize the variations brought by these factors, we standardized a number of controllable factors, such as operator, primers, reagents, equipments, and protocols. The technological adjustments made to our protocol were the natural progression from advancing our understanding of handling and evaluating salivary mRNA. Despite some of these differences in techniques between each cohort, we found that the association of these biomarker candidates with OSCC was highly consistent throughout all of the validation studies with IL-8 and SAT increased in patients with OSCC in all the cohort studies regardless of the specific method used.




Figure 1. Correlation of the 7 individual mRNA markers between UCLA laboratory and NCI-EDRN-BRL.

We have noted an operator training/experience effect in the ability to validate the salivary biomarkers. For cohorts 1 and 2, a new operator (J. Wang) conducted the validation assays. Cohort 1 validated 2 of 7 markers whereas in cohort 2, 7 of 7 markers were validated. Cohorts 3 to 5 were assayed at the NCI-EDRN-BRL, with a new operator (J. Reiss) conducting the assays. Cohort 3 validated 3 of 7 markers; cohort 4 validated 4 of 7 markers and cohort 5 validated 6 of 7 markers. This steady increase in the ability of operators to validate these markers points to the importance of technical training and competency.

Defining abnormal values is a critical step before the clinical implementation of any biomarker set. Our next

step in developing these mRNA signatures into clinically useful biomarkers includes standardizing measurements and characterizing the markers' distribution in the general population with regard to age, gender, smoking history, and ethnicity. The ability to screen individuals at risk for OSCC, using the biomarkers presented here with confirmation of diagnosis through imaging techniques and biopsy, will improve the clinicians' ability to detect tumors at a stage where therapeutic interventions still have a reasonable curative potential. Large-scale, prospective clinical trials using the PRoBE (21) design framework (using a fixed biomarker algorithm applied to subjects in an appropriate diagnostic clinical scenario) will ultimately determine the ability for these biomarkers to assess disease status in individual patients.

We are cognizant of the limitations of our current study in that these were case-control biomarker development studies. Midstream of our validation studies, in October 2008, the NCI-EDRN published a set of study design guidelines that are critical to be in place to eliminate bias for biomarker research (21). Four essential aspects of the study design that relate to the clinical context, biomarker performance criteria, the biomarker test, and study size were prescribed and must be vigorously followed. We did not incorporate these criteria into the design in the 5 case-control studies in the sense that the sample collection from patients with OSCC was retrospective after diagnosis and controls were healthy people. Collecting salivary specimens before biopsy for patients with OSCC will eliminate potential bias that the case-control study will inherit. Controls in our study

**Table 4.** Meta-analysis of the sensitivity and specificity individual markers across 5 independent cohorts

	Random-effects model	
	Sensitivity	Specificity
DUSP1	0.60	0.56
H3F3A	0.61	0.56
IL-1B	0.65	0.60
IL-8	0.68	0.64
OAZ1	0.62	0.58
S100P	0.60	0.56
SAT	0.66	0.63
IL-8	0.8	0.43
M2BP	0.74	0.4

**Table 5.** Predictive model comparisons for original 4 markers reported in the work of Li and colleagues (7) and stepwise selection across different cohorts

	Original 4 markers			Stepwise marker selection				
	Markers	AUC	Sensitivity	Specificity	Markers	AUC	Sensitivity	Specificity
Cohort 1	IL-8 + IL-1B + SAT + OAZ1	0.74	0.70	0.72	IL-8 + SAT + H3F3A + S100P	0.81	0.71	0.89
Cohort 2	IL-8 + IL-1B + SAT + OAZ1	0.86	0.79	0.77	IL-8 + IL-1B + SAT + OAZ1	0.86	0.79	0.77
Cohort 3	IL-8 + IL-1B + SAT + OAZ1	0.82	0.73	0.73	IL-8 + IL-1B + SAT + DUSP1	0.85	0.8	0.77
Cohort 4	IL-8 + IL-1B + SAT + OAZ1	0.75	0.64	0.75	IL-8 + IL-1B + S100P + OAZ1	0.78	0.64	0.86
Cohort 5	IL-8 + IL-1B + SAT + OAZ1	0.74	0.45	0.76	IL-8 + SAT + OAZ1 + S100P	0.75	0.87	0.56

would be appropriate if the clinical context is a general population screening on people who do not have an oral lesion. However, if the clinical context is to interpret oral lesions and identify who needs biopsies, a different type of controls, that is, who had oral lesions but without OSCC would be required. In addition, adding subjects with other types of oral pathology, such as periodontitis, leukoplakia, or caries, would help establish the specificity of the markers for OSCC rather than oral pathology generally. Therefore, we view our study as a prevalidation in particular to confirm the reproducibility of assay by an EDRN-BRL not an EDRN network validation study for an intended clinical use. We are currently enrolling subjects for a new study that is in strict adherence to the PRoBE design principles to discover and validate new salivary oral cancer biomarkers as well as determine the performance and use of the current markers in a PRoBE design setting (21).

The completion of Human Genome project and the development of technology such as microarray and proteomics provide new avenues for developing informative biomarkers. The successful identification of all proteins in human saliva by the joint effort Human Salivary Proteome project is representative of the promise for these technologies in discovering salivary analytes for normal health maintenance and disease detection (2). Combination of mRNA and protein markers may further push the power of predictability toward real-world biomarker application. Recent advances in bioinformatics tools will no doubt incorporate these multiple analyte categories to produce highly discriminatory "fingerprints" for the early detection and assessment of disease progression. The multiple avenues to salivary biomarker discovery can

provide optimism for the future of saliva diagnostics for oral cancer.

#### Role of the Sponsor

The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interests were disclosed.

#### Authors' Contributions

**Conception and design:** D. Elashoff, H. Zhou, D. Chia, E. Abemayor, D.T.W. Wong.

**Development of methodology:** D. Elashoff, H. Zhou, S. Hu, D. Chia, E. Abemayor, D.T.W. Wong.

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** D. Elashoff, H. Zhou, J. Reiss, J. Wang, M. Arellano, U. Sinha, D. Messadi, M. Wang, V. Nabili, M.W. Lingen, D. Akin, D.A. Kastratovic, D. Chia, E. Abemayor.

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** D. Elashoff, H. Zhou, D. Morris, T. Randolph, Z. Feng, D.A. Kastratovic, E. Abemayor.

**Writing, review, and/or revision of the manuscript:** D. Elashoff, H. Zhou, J. Wang, M. Arellano, U. Sinha, M. Wang, V. Nabili, M.W. Lingen, Z. Feng, D. Chia, E. Abemayor, D.T.W. Wong.

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** D. Elashoff, H. Zhou, M. Wang, E. Abemayor, D.T.W. Wong.

**Study supervision:** Z. Feng, D. Chia, E. Abemayor, D.T.W. Wong.

#### Grant Support

This study was supported by the NIH (R01DE017170, U01DE016275, and R21CA126733), the Barnes Family Trust Fund, and the Felix and Mildred Yip's Endowed Professorship.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 21, 2011; revised January 9, 2012; accepted January 23, 2012; published OnlineFirst February 1, 2012.

#### References

- Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. *J Am Dent Assoc* 2010;141:509-20.
- Dowling P, Wormald R, Meleady P, Henry M, Curran A, Clynes M. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. *J Proteomics* 2008;71:168-75.
- Franzmann EJ, Reategui EP, Carraway KL, Hamilton KL, Weed DT, Goodwin WJ. Salivary soluble CD44: a potential molecular marker for head and neck cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:735-9.
- Houali K, Wang X, Shimizu Y, Djennaoui D, Nicholls J, Fiorini S, et al. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. *Clin Cancer Res* 2007;13:4993-5000.



5. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. *Clin Cancer Res* 2008;14:6246–52.
6. Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers—a new diagnostic tool for oral cancer. *Clin Cancer Res* 2006;12:3979–84.
7. Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, et al. Salivary transcriptome diagnostics for oral cancer detection. *Clin Cancer Res* 2004;10:8442–50.
8. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. *Cancer Res* 2001;61:939–42.
9. Spafford MF, Koch WM, Reed AL, Califano JA, Xu LH, Eisenberger CF, et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. *Clin Cancer Res* 2001;7:607–12.
10. Franzmann EJ, Lundy DS, Abitbol AA, Goodwin WJ. Complete hypopharyngeal obstruction by mucosal adhesions: a complication of intensive chemoradiation for advanced head and neck cancer. *Head Neck* 2006;28:663–70.
11. Hu S, Wang J, Meijer J, leong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. *Arthritis Rheum* 2007;56:3588–600.
12. Li Y, Zhou X, St John MA, Wong DT. RNA profiling of cell-free saliva using microarray technology. *J Dent Res* 2004;83:199–203.
13. Hu Z, Zimmermann BG, Zhou H, Wang J, Henson BS, Yu W, et al. DTW Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids. *Clin Chem* 2008;54:824–32.
14. Ulmer TA, Keeler V, Loh L, Chibbar R, Torlakovic E, Andre S, et al. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. *J Cell Biochem* 2006;98:1351–66.
15. Park YP, Choi SC, Kim JH, Song EY, Kim JW, Yoon DY, et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. *Int J Cancer* 2007;120:813–20.
16. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. *Cancer Res* 2002;62:2535–9.
17. Wu CC, Chien KY, Tsang NM, Chang KP, Hao SP, Tsao CH, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. *Proteomics* 2005;5:3173–82.
18. Cooper H, Hedges L. *The handbook of research synthesis*. New York: Russell Sage Foundation; 1994.
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *Standards for Reporting of Diagnostic Accuracy*. *Clin Chem* 2003;49:1–6.
20. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, et al. Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. *PLoS One* 2009;4:e5875.
21. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. *J Natl Cancer Inst* 2008;100:1432–8.